Taipei, Oct. 26 (CNA) Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Basketball star Quincy Davis gets 1-month sentence for domestic violence
03/28/2024 06:13 PM - Culture
Second leg of Yoshitomo Nara art tour to open in Penghu Friday
03/28/2024 05:51 PM - Sports
Young boxing league breathes new life into Taiwan sport scene
03/28/2024 04:52 PM - Business
U.S. dollar closes lower on Taipei forex market
03/28/2024 04:17 PM - Society
Bongkrek acid suspected in deadly Taipei food poisoning outbreak
03/28/2024 02:42 PM